文献速递肝胆胰外科围术期管理与 ERAS

Grim表观遗传年龄加速可预测胰腺手术风险

Grim Age, Grim Prognosis: Epigenetic Aging Predicts Pancreatic Surgery Risk.
PubMed 文献 · Ann Surg · 2025-08-14

这项前瞻性队列研究纳入332例可切除胰腺导管腺癌患者,分析术前血液DNA甲基化时钟(Horvath、Pheno、Grim)与结局的关联。结果显示,术前Grim表观遗传年龄加速(EAA)较高与总生存期缩短、严重术后并发症增加及辅助化疗完成失败相关,提示其或可作为术前风险评估工具。

要点

  • 术前Grim EAA较高与可切除PDAC患者总生存期缩短独立相关(HR 1.12;95%CI 1.02-1.27;P=0.024)。
  • Grim EAA较高者严重术后并发症风险增加(OR 1.77;95%CI 1.16-2.68;P=0.008)。
  • Grim EAA较高者辅助化疗完成失败风险增加(OR 1.47;95%CI 1.20-1.81;P<0.0001)。

核心结论

  • Grim EAA或可作为可切除PDAC患者的术前风险评估工具,辅助个体化治疗决策。
  • 临床整合前仍需进一步外部验证。

研究设计与样本

  • 前瞻性队列研究,2009年7月至2023年5月纳入患者,随访至2024年8月。
  • 纳入18岁以上于哥本哈根大学医院Rigshospitalet计划接受胰腺手术的患者。
  • 排除非PDAC组织学、不可切除疾病、仅姑息性旁路手术或接受新辅助化疗者。
  • 共纳入332例患者,女性占45%,中位年龄69岁。
  • 术前血液样本DNA甲基化采用Infinium MethylationEPIC v2.0 Kit(Illumina)分析。

主要发现

  • 术前Grim EAA较高与总生存期缩短相关(HR 1.12;95%CI 1.02-1.27;P=0.024)。
  • 术前Grim EAA较高与严重术后并发症风险增加相关(OR 1.77;95%CI 1.16-2.68;P=0.008)。
  • 术前Grim EAA较高与辅助化疗完成失败风险增加相关(OR 1.47;95%CI 1.20-1.81;P<0.0001)。

临床怎么用

  • 对拟行胰腺切除的PDAC患者,可考虑检测术前Grim EAA以辅助识别并发症和辅助化疗完成风险较高者。
  • Grim EAA结果可用于术前咨询和个体化围术期管理,但目前尚不能作为常规决策依据。

局限性

  • 研究结论需进一步外部验证后方可临床整合。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association of Epigenetic age acceleration (EAA), measured using the Horvath, Pheno, and Grim clocks, with overall survival (OS), postoperative complications, and failure of adjuvant chemotherapy completion in patients with resectable pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Surgical resection is the only curative option for patients with PDAC. However, perioperative morbidity remains substantial, and existing risk assessments inadequately predict postoperative complications, adjuvant chemotherapy completion, and OS. EAA measures biological aging through DNA methylation patterns and may provide insights into these outcomes. METHODS: This prospective cohort study was conducted between July 2009 and May 2023, with follow-up extending to August 2024. Patients aged >18 who were scheduled for pancreatic surgery at Copenhagen University Hospital, Rigshospitalet, were included. Exclusion criteria were non-PDAC histology, non-resectable disease, salvage surgery (gastroenterostomy/hepaticojejunostomy only), or neoadjuvant chemotherapy. DNA methylation of preoperative blood samples was analyzed using the Infinium MethylationEPIC v2.0 Kit (Illumina). RESULTS: Among 332 patients (45% female, median age 69 y), higher preoperative Grim EAA was associated with reduced OS (hazard ratio (HR 1.12; 95% CI 1.02-1.27; P=0.024), increased severe postoperative complications (OR 1.77; 95% CI 1.16-2.68; P=0.008) and failure to complete adjuvant chemotherapy (OR 1.47; 95% CI 1.20-1.81; P<0.0001). CONCLUSION: Grim EAA may serve as a preoperative risk assessment tool for patients with resectable PDAC, potentially guiding personalized treatment. Further validation is required for clinical integration.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Kollbeck S, Hansen CP, Bonde MT, et al. Grim Age, Grim Prognosis: Epigenetic Aging Predicts Pancreatic Surgery Risk. Ann Surg. 2025. PMID: 40810414. doi:10.1097/SLA.0000000000006886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。